The Federal Cushion Under Your Drug Plan Premium Ends December 31. Watch the Drug List, Not the Premium.

If you or a parent buys a standalone Medicare drug plan, the federal program that’s been holding those premiums down stops at the end of this year. A letter explaining what your plan is doing about it shows up in September.

Don’t throw it out. That letter is the whole story.

Back in 2025, Medicare started paying prescription drug plan sponsors extra to keep premiums from lurching around while the industry absorbed the Inflation Reduction Act’s redesign of the drug benefit. The subsidy reduced the base beneficiary premium and capped how much a plan’s monthly premium could jump year over year. On July 28, CMS announced it’s ending after 2026, because bid analysis showed sponsors had “sufficient experience under the redesigned Part D benefit to support their assumptions.”

Translation: the training wheels come off January 1.

The numbers underneath are worse than the headline. The national average monthly bid amount for 2027 came in at $296.05, up about 24% in a year. The base beneficiary premium goes to $41.33 from $38.99, which is a rise of exactly 6%.

Exactly 6% is not a coincidence. The IRA caps growth in that figure at 6% a year through 2029. It’s the one number in Part D that legally cannot run away.

So here’s what they’re not telling you. CMS’s public framing is that most enrollees will see premium increases of under $10 a month, and some will see decreases. That may well be true. It’s also close to meaningless, because the premium is the lever plan sponsors are least able to pull. Facing a 24% jump in what coverage costs them, they reach for the levers that aren’t capped: the deductible, the tier a drug sits on, whether it needs prior authorization, and whether it’s on the list at all.

Your options are thinning too. Standalone drug plans went from 709 in 2024 to 360 in 2026. Avalere’s read is that ending the demonstration “could put further upward pressure on PDP premiums and accelerate market shifts in 2027 and beyond.”

A plan that keeps your premium flat and moves your one expensive prescription up two tiers didn’t save you anything.

So do this, and give it twenty minutes rather than two. When the Annual Notice of Change lands in September, open it with your actual pill bottles on the table. Go drug by drug. For each one, find the 2027 tier and the 2027 cost, and write the number next to what you pay now. Flag anything that moved tiers, picked up a prior authorization requirement, or vanished from the list.

Then compare. Final 2027 plan details publish in mid to late September, and open enrollment runs October 15 through December 7, with changes taking effect January 1. If your drugs came through clean, stay put and do nothing. Your plan renews on its own.

The premium is the number they’ll put in the mailer. The formulary is the number that empties your wallet at the counter.

How Candid Yak makes money. Some of the products we write about pay us if you apply or sign up through our links. That never changes our verdict, our rankings, or the numbers in this article. We call a bad deal a bad deal whether it pays us or not. Some brands shown in our comparison tools are placeholder examples while we finalize partner agreements, and we label them as such.